Released Presentations
PLENARY SESSIONS

FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?

Presentation
Maarten J. IJzerman, Professor & Vice-Dean, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Presentation
Peter Naredi, Professor of Surgery & Head, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and President, European CanCer Organization (ECCO), Brussels, Belgium
Presentation
Bettina Ryll, Founder, Melanoma Patient Network Europe and Chair, Patient Advocates Working Group, European Society for Medical Oncology (ESMO), Uppsala, Sweden
Presentation
Jason Arora, Director, Value-Based Healthcare, Medtronic, London, UK
Presentation
Luke Slawomirski, Health Economist & Policy Analyst, Directorate for Employment, Labour and Social Affairs, Organisation for Economic Co-operation and Development (OECD), Paris, France

 

SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?

Presentation
Susan Guthrie, Research Leader, Rand Europe, Cambridge, UK
Presentation
Nicola Allen, Senior Consultant, Global Pricing and Product Strategy, Precision Xtract, London, UK
Presentation
Zoe Garrett, Senior Technical Adviser, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), & Lead, JA3 Work Package 7, EUnetHTA, Manchester, UK

 

THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC

Presentation
Mandy Ryan, Director of the Health Economics Research Unit, Institute of Applied Health Sciences, College of Life Sciences and Medicine, University of Aberdeen, Aberdeen, UK
Presentation
Charles E. Phelps, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA
Presentation
Jérôme Wittwer, Professor, Economics, Bordeaux University, Bordeaux, France

 

ISSUE PANEL PRESENTATIONS

IP1 : PRAGMATIC CLINICAL TRIALS TO ESTIMATE TREATMENT EFFECTS: ARE THEY WORTH THE EFFORT?

Presentation
Helene Karcher, Managing Vice-President, Analytica Laser, Loerrach, Germany
Rita M. Kristy, Director - Statistics, Clinical and Outcomes Sciences, Astellas Pharma Global Development, Northbrook, IL, USA
Keith R. Abrams, Professor of Medical Statistics, NIHR Senior Investigator Emeritus & Head, Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK
Christoph Gerlinger, Senior Director, Development, Pharmaceuticals, Bayer AG, Berlin, Germany

 

IP2 : HOW TO IMPROVE CONSISTENCY OF ORPHAN DRUG PRICING AND REIMBURSEMENT IN EUROPE? APPLICATION OF THE 'ORPH-VAL' PRINCIPLES IN GERMANY, FRANCE, AND THE UNITED KINGDOM

Presentation
Lieven Annemans, Senior Full Professor of Health Economics, ICHER (Interuniversity Center for Health Economics Research), Ghent University - Brussels University, Ghent, Belgium
Francois Meyer, Advisor to the President, International Affairs, Haute Autorité de Santé (HAS), Saint-Denis, France
Sheela Upadhyaya, Associate Director, Centre for Health Technology Evaluation, Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE), London, UK
Karina Ehrig, Scientific advisor, Pharmaceuticals Department, Federal Joint Committee (G-BA), Berlin, Germany
Presentation
Francois Meyer, Advisor to the President, International Affairs, Haute Autorité de Santé (HAS), Saint-Denis, France

 

IP3 : UNMET (MEDICAL) NEED: SHOULD STAKEHOLDERS ALIGN ON A DEFINITION?

Presentation
Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium
Presentation
Claudine Sapede, Global HTA & Payment Policy Lead, F. Hoffmann-La Roche Ltd, Basel, Switzerland
Presentation
Jo De Cock, Administrateur General, INAMI - Institut National de l'Assurance Maladie-Invalidité, Brussels, Belgium
Presentation
Neil McAuslane, Director, Center for Innovation in Regulatory Science, London, UK

 

IP5 : EUROPEAN HTA 2020: WHAT IS THE ROAD MAP TO EFFECTIVE PERMANENT COOPERATION? (INVITED ISSUE PANEL)

Presentation
Wim Goettsch, Director, EUnetHTA JA3 Directorate, The National Healthcare Institute (ZIN), Diemen, The Netherlands
Presentation
Adrian Griffin, Vice President, HTA & Reimbursement Policy, Johnson & Johnson, Buckinghamshire, UK
Presentation
Nicola Bedlington, Secretary General, European Patients Forum (EPF), Brussels, Belgium
Presentation
Flora Giorgio, Head of Sector, Health Technology Assessment, Directorate General for Health and Food Safety (DG SANTE), European Commission, Brussels, Belgium

 

IP7 : 'MIND THE GAP!': HOW SHOULD WE MANAGE THE DIFFERENCE BETWEEN REGULATORY AND REIMBURSEMENT EVIDENCE REQUIREMENTS FOR MEDICAL DEVICES?

Presentation
Richard Charter, Head of Market Access & Pricing, EMEA, Becton Dickinson, Basel, Switzerland
Presentation
Karen Facey, Honorary Research Fellow and Evidence Based Healthcare Policy Consultant, University of Edinburgh, Edinburgh, UK
Presentation
Nneka C. Onwudiwe, PRO/PE Regulatory Review Officer, U.S. Government, Silver Spring, MD, USA

 

IP8 : FORECASTING PHARMACEUTICAL EXPENDITURE IN EUROPE: IS IT SUSTAINABLE?

Presentation
Panos Kanavos, Associate Professor in International Health Policy, LSE Health, Medical Technology Research Group, London School of Economics and Political Science, London, UK
Presentation
Jorge Mestre-Ferrandiz, Economist, Independent Economics Consultant, Madrid, Spain
Presentation
Tim Davis, Senior Principle, Consulting, QuintilesIMS, Basel, Switzerland

 

IP9 : SHOULD RARE ONCOLOGY TREATMENTS BE CONSIDERED TRUE ORPHANS?

Presentation
Elangovan Gajraj, Senior Technical Adviser, Scientific Advice, National Institute for Health and Care Excellence, London, UK
Annabel Griffiths, Consultant - Rare Diseases Lead, Costello Medical Consulting Ltd, Cambridge, UK
Ivana Cattaneo, Public Affairs Director, Novartis Oncology Europe, Novartis Farma S.p.A, Origgio (VA), Italy
Pan Pantziarka, Project Co-ordinator, Anti-Cancer Fund, Strombeek-Bever, Belgium

 

IP10 : DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?

Presentation
Mark Sculpher, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Presentation
Karl Claxton, Professor of Economics, Centre for Health Economics and Department of Economics, University of York, York, UK
Presentation
Jens Grueger, Head Global Pricing & Market Access, F. Hoffmann-LaRoche, Division Pharma, Basel, Switzerland

 

IP11 : DETERMINING VALUE IN HEALTH TECHNOLOGY ASSESSMENT CONSISTENT WITH SOCIETAL AIMS: PURSUE NEW OPTIONS?

Presentation
John Brazier, Professor of Health Economics and Dean, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
Presentation
Alistair McGuire, Professor, Health Economics at the LSE Health and Social Care, Social Policy, London School of Economics and Political Science, London, UK
Presentation
Michael Schlander, Professor of Health Economics at the University of Heidelberg, Head of the Division of Health Economics at the German Cancer Research Center, and Foundation Chairman & Scientific Director, Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany

 

IP12 : WHAT SHOULD PATIENT-CENTERED CARE MEAN IN THE WELFARE STATES OF EUROPE? THE UNITED KINGDOM AND GERMANY CANNOT BOTH BE RIGHT

Presentation
Axel C. Mühlbacher, Professor, Health Economics and Health Care Management, Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany
Nancy Devlin, Research Director, Office of Health Economics, London, UK
F. Reed Johnson, Professor, Duke Clinical Research Institute, Durham, NC, USA

 

IP13 : MCDA VALUATION AND ICERS – CAN THEY ALIGN FOR DECISION-MAKING PURPOSES? (INVITED ISSUE PANEL)

Presentation
Nancy Devlin, Research Director, Office of Health Economics, London, UK
Presentation
Maarten Ijzerman, Professor & Vice-Dean, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Presentation
Louis P. Garrison, Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy University of Washington, Seattle, WA, USA
Presentation
Charles E. Phelps, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA

 

IP14 : PATIENT-CENTERED DECISION MAKING: HOW DO YOU GENERATE RELEVANT PATIENT-REPORTED OUTCOMES EVIDENCE FOR CHRONIC DISEASE MANAGEMENT AND MARKET-ACCESS DECISION MAKING?

Presentation
Finn Børlum Kristensen, Professor, Faculty of Health Sciences, University of Southern Denmark, Hilleroed, Denmark
Presentation
Katharine Barnard, Visiting Professor, Bournemouth University, Poole, UK
Presentation
Francois Meyer, Advisor to the President, International Affairs, Haute Autorité de Santé (HAS), Saint-Denis, France
Katharine Barnard, Visiting Professor, Bournemouth University, Poole, UK
Simon O'Neill, Director of Health Intelligence and Professional Liaison, Diabetes UK, London, UK

 

IP15 : A MODEST PROPOSAL: CAN WE EASE THE BURDEN OF MYRIAD MEASURES WITH A MINIMUM DATA SET THAT ACTUALLY MATTERS TO PATIENTS?

Presentation
Bettina Ryll, Founder, and Researcher, Melanoma Patient Network Europe, and Uppsala University (Department EBC), Uppsala, Sweden
Presentation
Roman Casciano, Executive Vice President & General Manager, Consulting & Analytics & Global Head, Value & Access, ANALYTICA LASER, New York, NY, USA
Presentation
Charles D. Petrie, Vice President, Outcomes and Evidence, Global Health & Value, Pfizer, Inc., Groton, CT, USA

 

IP16 : MANAGED ENTRY SCHEMES FOR MEDICAL DEVICES: GREAT OPPORTUNITY OR MAJOR CHALLENGE?

Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Aleksandra Torbica, Professor, Bocconi University, Milano, Italy
Presentation
Richard Charter, Head of Market Access & Pricing, Becton Dickinson, Allschwil, Switzerland

 

IP17 : DERIVING UTILITY MEASURES FROM DISEASE-SPECIFIC QUALITY OF LIFE INSTRUMENTS: DOES MAPPING TO GENERIC UTILITY INSTRUMENTS ADEQUATELY CAPTURE THE PATIENT PERSPECTIVE IN ECONOMIC EVALUATION?

Presentation
Keith Tolley, Director, Tolley Health Economics Ltd., Buxton, UK
Presentation
Linda Abetz-Webb, Senior Research Director, Patient-Centred Outcomes Assessments, Bollington, UK

 

IP18 : HOW WILL HEALTH CARE SYSTEMS HANDLE FUTURE ONCOLOGY COMBINATION PRODUCT LAUNCHES?

Presentation
Bettina Ryll, Founder, and Researcher, Melanoma Patient Network Europe, and Uppsala University (Department EBC), Uppsala, Sweden

 

IP19 : CAN THE PATIENT VOICE BE BETTER INCORPORATED INTO THE NICE PROCESS?

Presentation
Jennifer Lee, HEMAR & Advocacy Director, Health Economics, Market Access, Reimbursement, & Advocacy, Janssen UK, High Wycombe, UK
Eric Low, Former CEO of Myeloma UK, N/A, East Lothian, UK
Heidi Livingstone, Project Manager, Patient and Public Involvement Manager, NICE, London, UK
Richard Jackson, Patient Expert (Currently a Primary School Headteacher), NA (Hillview Primary School), NA, UK

 

IP20 : SHOULD ICER BE NICE (OR NOT)? HOW ICER’S NEW COST-EFFECTIVENESS FRAMEWORK COMPARES WITH NICE’S GUIDELINES

Presentation
Dan Ollendorf, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, MA, USA
Pall Jonsson, Associate Director, Research and Development, National Institute for Health and Care Excellence (NICE), Manchester, UK
Matthew Sussman, Associate Managing Director/Director, Modeling & Evidence, Boston Health Economics, Waltham, MA, USA
Presentation
Pall Jonsson, Associate Director, Research and Development, National Institute for Health and Care Excellence (NICE), Manchester, UK

 

IP21 : ADAPTIVE PATHWAYS FOR TRANSFORMATIVE MEDICINAL PRODUCTS: A NEW PARADIGM WITH THE ENHANCED APPLICATION OF REAL-WORLD EVIDENCE?

Presentation
Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium
Rob Thwaites, Senior Director, Takeda, London, UK
David Schwicker, Principal, ORPHA Strategy Consulting, Basle, Switzerland
Ad Schuurman, Head of the International Department, National Health Care Institute (ZIN), AH, The Netherlands

 

IP22 : HOW CAN WE ASSESS THE VALUE OF NEW ANTIBIOTICS?

Presentation
Adrian Towse, Director, Office of Health Economics, London, UK
Presentation
Alec Morton, Professor of Management Science, Department of Management Science, Strathclyde Business School, University of Strathclyde, Glasgow, Scotland, UK
Presentation
Douglas Lundin, Chief Economist, TLV, Stockholm, Sweden
Presentation
Chris Henshall, Independent Consultant and Visiting Fellow, Office of Health Economics, London, UK, UK

 

IP23 : HOW DO YOU INCORPORATE THE PATIENT PERSPECTIVE INTO HEALTH TECHNOLOGY ASSESSMENTS? DEFINING BEST PRACTICES FOR RIGOROUS SCIENTIFIC EVIDENCE AND IMPACTFUL SUBMISSIONS AND REVIEWS

Presentation
Judith Leah Rubinstein, Director of Regulatory Data, Context Matters Inc., New York, NY, USA
Laure Delbecque, Associate Director, Pharmerit International, Rotterdam, The Netherlands
Ken Bond, Director, Patient Engagement, Ethics, and International Affairs, CADTH, Ottawa, ON, Canada
Paola Kruger, Patient Expert-EUPATI Fellow, Accademia dei Pazienti/EUPATI Italia, Rome, Italy

 

IP24 : TRUSTING THE RESULTS OF MODEL-BASED ECONOMIC ANALYSES: IS THERE A PRAGMATIC VALIDATION SOLUTION?

Presentation
Matt Stevenson, Professor of Health Technology Assessment, ScHARR, University of Sheffield, Sheffield, UK
Presentation
Jorgen Moller, Vice President of Modeling Technologies, Modelling Technologies and Simulation, Evidera, Hammersmith, UK
Presentation
Salah Ghabri, Senior Health Economist, Haute Autorité de Santé, Saint-Denis La Plaine, France

 

IP25 : INNOVATIVE CLINICAL TRIAL DESIGNS: WELCOMED BY REGULATORS BUT WHAT ABOUT THE PAYERS?

Presentation
Richard Macaulay, Principal Consultant, PAREXEL Access Consulting, PAREXEL International, London, UK
Detlev Parow, Head of Health Care Management Development, D A K - Gesundheit, Hamburg, Germany
Leanne Larson, Vice President & Global Head, Observational Research, PAREXEL International, Waltham, MA, USA
Andrew Walker, Director, Salus Alba Consulting, Glasgow, UK

 

IP26 : MHEALTH AMONG CLINICIANS AND PATIENTS IN CANCER CARE: HOW TO ADDRESS THE DIGITAL DIVIDE?

Presentation
Rosanna Tarricone, Associate Dean, Government & Health Division, SDA Bocconi, Director, Centre for Research on Health and Social Care Management, Associate Professor, Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy
Presentation
Maria Cucciniello, Assistant Professor, Centre for Research on Health and Social Care Management (CERGAS) and Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy
Presentation
Roma Maguire, Professor, School of Health Sciences Faculty of Health & Medical Sciences, University of Surrey, Glasgow, UK
Presentation
Nicola Scalzo, Policy and Legal Officer, DG for Internal Market, Industry, Entrepreneurship and SMEs Health Technology and Cosmetics Unit GROW D.4, European Commission, Brussels, Belgium

 

IP27 : VALUING CHILDREN'S HRQoL FOR HEALTH TECHNOLOGY ASSESSMENT: WHAT ARE THE ISSUES AND CHALLENGES?

Presentation
Nancy Devlin, Director of Research, Office of Health Economics, London, UK
Presentation
Donna Rowen, Senior Research Fellow, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

 

IP28 : PATIENT PREFERENCES IN EUROPEAN DRUG REGULATION – ARE WE READY?

Presentation
Pierre Demolis, Chairman Oncology Working Party of the CHMP, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Saint-Denis, France

 

WORKSHOP PRESENTATIONS

W1 : WHERE DO WE NEED GOOD RESEARCH PRACTICE GUIDANCE IN HEALTH TECHNOLOGY ASSESSMENT?

Presentation
Wim Goettsch, Director EUnetHTA JA3, EUnetHTA JA3 Directorate, The National Healthcare Institute (ZIN), Diemen, The Netherlands
Finn Børlum Kristensen, Professor, Faculty of Health Sciences, University of Southern Denmark, Hilleroed, Denmark
Mirjana Huić, Assistant Director, Department for Development, Research and Health Technology Assessment, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia
Sophie Werkö, Project Director, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden

 

W2 : PATIENT POWERED REGISTRIES: USEFUL FOR HEALTH TECHNOLOGY ASSESSMENT OR NOT?

Presentation
Elisabeth M. Oehrlein, PhD Candidate, Dept. of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
Gurmit Sandhu, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland
Robert N. McBurney, Co-Principal Investigator, iConquerMS™ - the MS Patient-Powered Research Network, Accelerated Cure Project for MS, Waltham, MA, USA
Chantal Guilhaume, Scientific Project Manager, EUnetHTA JA3; Direction de l'Evaluation Médicale, Economique et de Santé Publique (DEMESP), Haute Autorité de Santé, Saint-Denis La Plaine, France

 

W5 : SUSTAINABLE FUNDING AND FAIR PRICING FOR ORPHAN DRUGS: WHAT ARE THE SOLUTIONS?

Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Saskia Knies, Senior Advisor Pharmacoeconomics, National Health Care Institute (ZiN), Diemen, The Netherlands
Presentation
Martina Garau, Principal Economist, Office of Health Economics, London, UK

 

W6 : GENERATING REAL-WORLD EVIDENCE FOR REAL-WORLD DECISIONS: APPLICATION OF ADVANCED METHODS

Presentation
Richard Grieve, Professor of Health Economics Methodology, London School of Hygiene and Tropical Medicine, London, UK
Presentation
Mark Sculpher, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Presentation
Anirban Basu, Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

 

W7 : VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS: EMERGING GOOD PRACTICE RECOMMENDATIONS FROM THE ISPOR VOI TASK FORCE

Presentation
Elisabeth Fenwick, Senior Principal, Health Economics, Health Economics & Epidemiology, ICON plc, Abingdon, UK
Hendrik Koffijberg, Associate Professor Health Economics, Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Saskia Knies, Senior Advisor Pharmacoeconomics, National Health Care Institute (ZiN), Diemen, The Netherlands
Claire Rothery, Senior Research Fellow, Centre for Health Economics, University of York, York, UK

 

W8 : MODELING SEPARATE LINES OF TREATMENT VERSUS TREATMENT SEQUENCES IN CANCER

Presentation
Sonja Sorensen, Senior Director, Senior Research Leader, Modeling & Simulation, Evidera, Bethesda, MD, USA
Matthew Stevenson, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield, Sheffield, UK
Agnes Benedict, Executive Director, Evidera, Budapest, Hungary

 

W10 : EQ-5D: IS NICE READY FOR THE NEXT LEVEL?

Presentation
Nancy Devlin, Director of Research, Office of Health Economics, London, UK
Presentation
Allan Wailoo, Professor of Health Economics, School of Health and Related Research, University of Sheffield, Sheffield, UK
Presentation
Rosemary Lovett, Senior Scientific Adviser, Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE), London, UK

 

W11 : DETERMINING THE VALUE OF LONG TERM OUTCOMES ASSOCIATED WITH IMMUNO-ONCOLOGY THERAPIES - CHALLENGES AND APPROACHES FOR OS EXTRAPOLATIONS

Presentation
Nicholas Latimer, Senior Research Fellow, ScHARR, University of Sheffield, Sheffield, UK
Presentation
Pralay Mukhopadhyay, Statistician, Astrazeneca, Gaithersburg, MD, USA
Presentation
Andrew Briggs, Visiting Investigator, Center for Health Policy and Outcomes, Department of Epidemiology & Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

 

W12 : GETTING TO THE HEART OF THE MATTER: REAL-WORLD EVIDENCE AS AN INDISPENSABLE SOURCE FOR THE ONGOING ASSESSMENT OF CARDIOVASCULAR TREATMENTS

Presentation
Kathleen E. Hughes, Vice President, Avalere Health LLC, Washington, DC, USA
Colin Berry, Professor, University of Glasgow, Glasgow, UK
Yi Qian, Director, Amgen, Thousand Oaks, CA, USA
Pall Jonsson, Associate Director, Research and Development, National Institute for Health and Care Excellence (NICE), Manchester, UK

 

W15 : TIME FOR A CHANGE? ALTERNATIVE APPROACHES TO MODELLING IN CANCER VALUE ASSESSMENTS

Presentation
Robert Hettle, Vice President (Technical) of Health Economic modelling, HERON Commercialization, PAREXEL International, London, UK
Presentation
Marta Soares, Senior Research Fellow, Team for Economic Evaluation and Health Technology Assessment (TEEHTA), Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Meindert Boysen, Professor, Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, and Programme Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), London, UK
Presentation
Beth Woods, Senior Research Fellow, Team for Economic Evaluation and Health Technology Assessment (TEEHTA), Centre for Health Economics, University of York, Heslington, York, UK

 

W16 : UNDERSTANDING THE VALUE AND FEASIBILITY OF ENGAGING PATIENTS IN THE DESIGN OF CLINICAL TRIALS AND CLINICAL OUTCOME ASSESSMENT MEASUREMENT STRATEGIES: INSIGHTS FROM EXPERIENCES IN ONCOLOGY AND GOUT

Presentation
Sophi Tatlock, Associate Director, Patient-Centered Outcomes, Adelphi Values Ltd, Bollington, Cheshire, UK
Bryan Bennett, Director, Patient-Centered Outcomes, Adelphi Values Ltd, Bollington, Cheshire, UK
Stephanie Manson, Senior Director, HEOR Excellence, Novartis, East Hanover, NJ, USA
Katja Rudell, Teaching Fellow, Queen Mary University of London, London, UK

 

W17 : COMPARING, CONTRASTING, AND VALIDATING HEALTH ECONOMIC DECISION MODELS: EXPERIENCES FROM THE LATEST MT. HOOD CHALLENGE IN DIABETES AND LESSONS FOR OTHER DISEASE AREAS

Presentation
Mark Lamotte, Cardiologist, Senior principal, RWES, QuintilesIMS, Zaventem, Belgium
Michael Willis, Research Director, The Swedish Institute for Health Economics, Lund, Sweden
Talitha Feenstra, Senior Researcher / Assistant Professor, RIVM /UMCG, Bilthoven, The Netherlands
Alan Brennan, Professor of Health Economics and Decision Modelling, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

 

W18 : FROM ONE TO MANY: WHEN GROUPS – NOT CZARS – MAKE DECISIONS

Presentation
Charles E. Phelps, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA
Guruprasad Madhavan, Senior Program Officer, Health and Medicine, National Academies of Science, Engineering, and Medicine, Washington, DC, USA

 

W19 : GENERATING EVIDENCE TO SUPPORT OFF-LABEL HIGHER VALUE CANCER TREATMENT REGIMENS

Presentation
Mark Sculpher, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Presentation
Mark J. Ratain, Leon O. Jacobson Professor, Department of Medicine, The University of Chicago, CHICAGO, IL, USA
Presentation
Peter Clark, Professor, The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK
Presentation
Virginia Acha, Executive Director, EU, EMEA, APAC Regulatory Policy, MSD Ltd., Hertfordshire, UK

 

W20 : DISCONNECTED OR LIMITED EVIDENCE IN NETWORK META-ANALYSIS: WHAT CAN BE DONE?

Presentation
Howard Thom, Research Fellow in Statistical Modelling, School of Social and Community Medicine, University of Bristol, Bristol, UK
Presentation
Jeroen P. Jansen, Chief Scientist of Evidence Synthesis and Decision Modeling, Evidence Synthesis and Decision Modeling, Precision Health Economics, Vancouver, BC, Canada
Presentation
Joy Leahy, PhD Student, School of Computer Science and Statistics, Trinity College Dublin, Dublin 2, Ireland

 

W21 : COMPARING TREATMENTS BY COMBINING DATA FROM VARIOUS RANDOMIZED AND OBSERVATIONAL STUDIES: INTRODUCTION TO CONCEPT, METHODS, AND APPLICATION

Presentation
Farhan Mughal, Associate Director, Health Economics and Outcomes Research, Celgene Ltd, Uxbridge, UK
Susanne Schmitz, Postdoctoral Fellow, Department of Population Health / Health Economics and Evidence Synthesis Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg
Viktor Chirikov, Scientist, Pharmerit International, Bethesda, MD, USA

 

W22 : NEGOTIATING PRICE AND DATA IN AN ERA OF CONDITIONAL APPROVAL: “STICK” OR “TWIST”?

Presentation
Daniel Gladwell, Principal Consultant, BresMed Health Solutions LTD, Sheffield, UK
Ash Bullement, Health Economist, BresMed Health Solutions, Sheffield, UK
Warren Cowell, National Market Access Policy Lead, Janssen Inc., High Wycombe, UK
Alan Brennan, Professor, University of Sheffield, Sheffield, UK

 

W23 : IMPROVING PERFORMANCE OF ALGORITHMS TO POWER UNMET NEED AND EFFECTIVENESS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH USING ELECTRONIC HEALTH RECORDS AND HEALTH CARE CLAIMS DATA SOURCES

Presentation
Schiffon L Wong, Franchise Head Neurology, Global Evidence & Value Development, Global Research & Development, EMD Serono, Inc., Billerica, MA, USA
Aaron WC Kamauu, CEO, Anolinx LLC, Salt Lake City, UT, USA
Hoa Van Le, Senior Consultant, PAREXEL INTERNATIONAL, DURHAM, NC, USA
Monica Gaines Kobayashi, Consultant, Real World Evidence & Data Analytics, PAREXEL International, Durham, NC, USA

 

W24 : POPULATION-ADJUSTED TREATMENT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT: AN OVERVIEW OF APPROACHES AND PERSPECTIVES

Presentation
Nicky J. Welton, Reader in Statistical and Health Economic Modelling, School of Social and Community Medicine, University of Bristol, Bristol, UK
Presentation
Mark Belger, Principal Research Scientist, Eli Lilly and Company, Surrey, UK
Presentation
David M. Phillippo, Research Associate in Evidence Synthesis, School of Social and Community Medicine, University of Bristol, Bristol, UK

 

ISPOR FORUMS

F2 : METHODS AND PRELIMINARY RESULTS OF THE ISPOR ONCOLOGY HEALTH ECONOMIC MODELING SPECIAL INTEREST GROUP

Presentation
Agnes Benedict, Executive Director, Evidera, Budapest, Hungary
Noemi Muszbek, Senior Research Scientist, Evidera, London, UK
Hena Qureshi, Student, Community Health Sciences, University of Calgary, Calgary, AB, Canada
Nermeen Nabil Ashoush, Lecturer in Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt

 

F3 : RARE DISEASE RESEARCH, HTA AND EVIDENCE FOR REIMBURSEMENT

Presentation
Ken Redekop, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
Christopher M. Blanchette, Associate Professor, University of North Carolina, Charlotte, NC, USA & VP, Precision Health Economics, Charlotte, NC, USA
Sheela Upadhyaha, Associate Director Highly Specialised Technologies, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence, London, UK
Janis Clayton, VP and General Manager UK & Ireland, PTC Therapeutics Ltd., Dublin, Ireland
Sandra Nestler-Parr, Managing Director, Rare Access Ltd., London, UK

 

F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?

Presentation
Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium
Presentation
Federico Augustovski, Director, Health Technology Assessment & Economic Evaluations Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina
Presentation
Diego F Guarin, Senior Director, HEOR & HTA Strategy, HEOR & HTA, Latin America, Merck-Serono, Billerica, MA, USA
Presentation
Diego Rosselli, Associate Professor, Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, Colombia
Presentation
Ramiro E. Gilardino, Director, Global Networks Latin America, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Lawrenceville, NJ, USA

 

F5 : RARE DISEASES MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES

Presentation
Tarik Catic, Consultant, Health Economics and Pharmacoeconomics, Sarajevo, Bosnia
Presentation
Rok Hren, President, ISPOR Slovenia Chapter, Assistant Professor, Institute of Mathematics, Physics and Mechanics, Ljubljana, Slovenia
Presentation
Olha Zaliska, Professor, The Head of Department of Management & Economy of Pharmacy and Medicine Technology, Postgraduate Faculty, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Presentation
John Yfantopoulos, President, ISPOR Greece Chapter, Professor, Health Economics, University of Athens, Athens, Greece

 

F6 : THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES

Presentation
Joanna Lis, Adjunct, Faculty of Pharmacy, Department of Pharmacoeconomics, Medical University of Warsaw, Director, Market Access, Sanofi, Warsaw, Poland
Presentation
Mary Geitona, Professor, Health Economics, Department of Social and Educational Policy, University of Peloponnese, Korinthos, Greece
Presentation
Dragana Atanasijevic, President, ISPOR Serbia Chapter, Senior Researcher, Institute of Public Health of Serbia, Belgrade, Serbia
Presentation
Zoltan Kalo, Professor of Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary

 

F7 : HEALTH STATE UTILITY (HSU) IDENTIFICATION AND USE IN COST-EFFECTIVENESS IN DECISION MODELLING - AN ISPOR TASK FORCE

Presentation
John Brazier, Professor of Health Economics and Dean, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
Roberta Ara, Senior Research Fellow, School of Health and Related Research, The University of Sheffield, Sheffield, UK
Andrew Lloyd, Director, Acaster Lloyd Consulting Ltd., Oxford, UK
Helene Chevrou-Severac, HEOR Director, Medical Affairs, Celgene International, Boudry, Switzerland

 

F8 : INNOVATION AND MARKET ACCESS IN ASIA-PACIFIC: WHAT EVIDENCE AND PROCESSES ARE APPROPRIATE FOR REIMBURSEMENT? CHINA, JAPAN, SOUTH KOREA, TAIWAN AND AUSTRALIA COMPARED.

Presentation
Chee-Jen Chang, President, Taiwan Society for Pharmacoeconomics and Outcome Research, Director, Clinical Informatics and Medical Statistics Research Center, and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Tao Yuan, Taiwan
Presentation
Shanlian Hu, Senior Consultant, Shanghai Health Development Research Center, Shanghai, China
Presentation
Mendel Grobler, Director and Head of Health Policy – JAPAC and Emerging Markets, Amgen Inc., North Ryde, NSW, Australia
Presentation
Bruce Crawford, Vice President, Real World Evidence & Insights, InVentiv Health Japan G.K., Tokyo, Japan
Presentation
Sukyeong Kim, Director, Coordinating Center for National Health Clinical Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)

 

F9 : LATE STAGE ONCOLOGY MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES

Presentation
Oresta Piniazhko, President, ISPOR Ukraine Chapter, Assistant Professor, Member of Expert Committee of MoH, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Presentation
Aleksandra Zawodnik, PhD Candidate, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
Presentation
Bertalan Nemeth, Senior Pharmacoeconomist, Syreon Research Institute, Budapest, Hungary

 

F10 : THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE

Presentation
Josip Culig, Professor, Pharmacology & Clinical Pharmacology & Head, Pharmacoepidemiology Department, Andrija Stampar Institute of Public Health, Zagreb, Croatia
Presentation
Maria Kamusheva, Assistant Professor, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
Presentation
Konstantin Tachkov, PhD student, Medical University of Sofia, Sofia, Bulgaria
Presentation
Tamas Agh, Principal Researcher, Syreon Research Institute, Hungary, Hungary

 

F12 : IMPLEMENTING ADAPTIVE PATHWAYS IN EUROPE: A CENTRAL AND EASTERN EUROPE (CEE) FOCUS

Presentation
Dominik Tomek, President, ISPOR Slovakia Chapter, and Senior Researcher, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic
Presentation
Zoltan Kalo, Professor of Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary
Presentation
André Broekmans, Director Escher, Lygature and Coordinator, ADAPT SMART, Utrecht, The Netherlands
Presentation
Tomas Tesar, Member of the Reimbursement Committee, Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovakia

 

EDUCATIONAL SYMPOSIA

THE EVOLVING APPROACH TO DRUG VALUE ASSESSMENT IN GLOBAL MARKETS

Presentation
Aris Angelis, Research Fellow, Medical Technology Research Group, London School of Economics, London, UK
David Rees, Principal, Health Strategies Group, Yardley, PA, USA
Sanjay Shah, Principal, Visionary Ventures, LLC, Morganville, NJ, USA
Michael Schlander, Professor of Economics, University of Heidelberg, Chairman and Scientific Director InnoVal-HC, Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany
Andreas Wildi, Partner, Walderwyss Attorneys at Law, Zurich, Switzerland
Jennifer Cain Birkmose, Head of Market Access, Pricing and Policy, Region Europe, Roche, Basel, Switzerland

 

REAL-WORLD EVIDENCE TO SUPPORT REGULATORY APPROVALS BASED ON TUMOR BIOMARKERS IN ONCOLOGY RESEARCH

Presentation
Samuel Wagner, Executive Director, Worldwide HEOR, Global Health Economics and Outcomes Research, Bristol-Myers Squibb, Washington Crossing, PA, USA
Joshua Ray, Group Head Health Economics, F. Hoffmann-La Roche, Basel, Switzerland
Jonathan Kish, Director, HEOR, Cardinal Health Specialty Solutions, Dublin, OH, USA
Bruce Feinberg, Vice President, Chief Medical Officer, Cardinal Health Specialty Solutions, Dublin, OH, USA
Hui Huang, Executive Director, Head of Global Outcomes Research Oncology, Takeda, Cambridge, MA, USA

 

HTA V2.0: THE RELEVANCE OF REAL-WORLD EVIDENCE IN VALUE FRAMEWORKS AND ITS RELATION WITH REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT CONVERGENCE

Presentation
Jacco Keja, Vice President, Global Head Outcomes Research, QuintilesIMS, London, UK

 

CHANGING THE HEALTH TECHNOLOGY ASSESSMENT PARADIGM FOR COMBINATION THERAPIES

Presentation
Claudio Jommi, Professor, CERGAS, CERGAS Bocconi University, Milan, Italy
Mark Ratcliffe, Chief Executive Officer, PHMR Ltd, London, UK
Andrew Walker, Director, Salus Alba Consulting, Glasgow, UK
J. Jaime Caro, Chief Scientist, Evidera, Bethesda, MD, USA
Hanim Edoo, Early Engagement & Patient Access Consultant, Medi-Qualite Omega, Paris, France

 

UNIVERSAL VALUE: THE WAY FORWARD?

Presentation
Michael Blackney, Principal Consultant, Covance Market Access, London, UK
Michael F. Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Emanuela Castelnuovo, Director, Covance Market Access, London, UK
Ruth Zeidman, Director, Covance Market Access, London, UK
Don Redding, Director of Policy, National Voices, London, UK

 

PODIUM AND POSTER PRESENTATIONS


For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 20th Annual European Congress, see: the ISPOR Scientific Presentations Database an electronic database of nearly 44,500 research papers presented at ISPOR International Conference, ISPOR European Conference, and ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Scientific Presentations Database
  • Under Meeting select ISPOR 20th Annual European Congress – Glasgow, Scotland
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
OPEN MEETINGS

ISPOR Nutrition Economics Special Interest Group

ISPOR PATIENT REPORTED OUTCOMES RESEARCH SPECIAL INTEREST GROUP OPEN MEETING

ISPOR Stated Preference Methods Special Interest Group

ISPOR BIOSIMILAR SPECIAL INTEREST GROUP OPEN MEETING

ISPOR PATIENT CENTERED SPECIAL INTEREST GROUP OPEN MEETING

ISPOR MEDICAL DEVICES AND DIAGNOSTICS SPECIAL INTEREST GROUP OPEN MEETING

Women in HEOR/Science

EDUCATIONAL FORUM

Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as Evidence-Based Health Technology Assessment (HTA) specifically for Off-Patent Pharmaceuticals in Emerging Markets

Presentation
Zoltán Kaló, Professor, Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary
Diane Brixner, Professor, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
Budi Hidayat, Professor, Health Economics & Health Insurance, University of Indonesia, Jakarta, Indonesia
Pham Huy Tuan Kiet, Professor, Department of Health Economics, Hanoi Medical University, Hanoi, Vietnam
Erna Kristin, Lecturer, Department of Pharmacology & Therapy of Medicine, Gadjah Mada University, Yogyakarta, Indonesia
Nikos Maniadakis, Professor, National School of Public Health, Athens, Greece
Kalman Wijaya, Senior Manager, Global Market Access and Policy, Abbott, Allschwil, Switzerland

 

STUDENT SHOWCASE
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.